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Adipose Tissue Imaging
The Potential and the Challenge*
Robert J. Gropler, MD, Linda R. Peterson, MD
St. Louis, MissouriThe metabolic syndrome is a vexing problem for the
cardiologist, internist, and endocrinologist. It is a
constellation of peripheral signs that indicate insu-
lin resistance in patients but does not quantify it.
The metabolic syndrome helps the physician to
identify patients who are at increased risk of
cardiovascular disease (CVD) with a simple physi-
cal examination and standard laboratory findings.
Indeed, the presence of the metabolic syndrome
See page 843
reminds us that the cardiovascular system is part of
an integrated whole, and as such, is affected by
disease processes that involve other key tissues and
organs. However, exactly how the metabolic syn-
drome confers this increased risk of CVD is poorly
understood. For example, the relative importance in
conferring increased CVD risk of each component
is unknown. In this regard, it is especially nebulous
how increased abdominal girth, one of the hall-
marks of the metabolic syndrome, increases CVD
risk. For example, increased abdominal girth is
associated with insulin resistance and diabetes mel-
litus, both of which increase CVD risk. Moreover,
it occurs typically with obesity, another known risk
factor for CVD. Consequently, the unique biolog-
ical attributes of increased abdominal girth that
contribute to increased CVD risk are unclear.
The first imaging studies that evaluated how
increased abdominal girth may relate to increased
CVD risk demonstrated that it was visceral adipose
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Edward Mallinckrodt Institute of Radiology, Cardiovascular
Division, Department of Internal Medicine, Washington University
School of Medicine, St. Louis, Missouri.tissue (VAT) burden, as opposed to the burden of
subcutaneous abdominal tissue (SAT), that was
most closely associated with CVD risk. Both com-
puted tomography and cardiac magnetic resonance
imaging have been used to quantify the volume of
VAT and SAT (1). However, current dedicated
computed tomographic and cardiac magnetic reso-
nance imaging techniques are limited to measuring
the structure, not in vivo metabolism, of these
adipose depots. The study by Christen et al. (2) in
this issue of iJACC moves beyond these techniques,
using 18F-fluorodeoxyglucose and positron emis-
sion tomography (PET) to measure the glucose
metabolism of the different fat depots, which are
colocalized with adipose structures using combined
PET/computed tomography. This technique for
determining the 18F-fluorodeoxyglucose uptake ac-
tivity of adipose tissue at different depots (i.e., VAT
vs. SAT) is depicted in Figure 1 of that article.
Although colocalization with PET/computed to-
mography is used extensively in oncology, its appli-
cation for the evaluation of adipose tissue is new.
As expected, the authors found that VAT, which
is often described as metabolically active, had a
higher glucose uptake than SAT. However, there
were no differences between the glucose uptake by
lean subjects’ VAT and the obese subjects’ VAT.
Because an increased amount of VAT is associated
with increased inflammation, infiltration, and acti-
vation of tissue macrophages; hypertrophied meta-
bolically active fat cells; and an adverse adipokine
profile (e.g., less adiponectin, more leptin) (3), one
might have expected the VAT in obese subjects to
have greater glucose uptake than that in lean sub-
jects. However, this finding is similar to that of
another study, which suggested that total glucose
uptake by VAT is not different in normal controls
compared with that in obese subjects with and
without diabetes mellitus (4). Because the amount
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Editorial Comment
853f VAT is expected to be less in the lean than the
bese, this suggests that the VAT of lean subjects
as a higher glucose uptake per kilogram, a finding
hat been observed by others (4). Moreover, as
ointed out by the authors, it is likely that VAT in
bese subjects exhibits lower glucose uptake per
ilogram due to insulin-resistant adipocytes.
Christen et al. (2) not only imaged the glucose
ptake from the adipose depots from different
ocations, but they also determined from laboratory
tudies that the stromal vascular cells from VAT
ake up more glucose than stromal vascular cells
rom SAT (at baseline and after stimulation with
umor necrosis factor  interleukin-1). Unfortu-
ately, they did not also evaluate the in vitro glucose
ptake of the adipocytes of the VAT and SAT as
ell. Nevertheless, it appears that some of the
ncreased glucose metabolic activity of VAT is due
o the company that its adipocytes are keeping as
pposed to the adipocytes themselves.
Thus, this article moves our understanding be-
ond the initial findings that 1) not all adipose
issue is alike and 2) adipocytes can make and
espond to hormones and cytokines to realizing that
dipose tissue is a complex environment composed
f varying amounts of many different types of cells
ncluding the stromal vascular cell fraction (which
ncludes inflammatory cells, mesenchymal stemCardiol Img 2010;3:843–51. vascular fraction celrecursors) (5). Recent studies have also demon-
trated that the extracellular matrix also influences
dipose activity and inflammation (6). All these
ypes of cells and extracellular matrix are influenc-
ng one another’s activity, and the sum of their
ctivity is the activity of the tissue as a whole.
From an imaging perspective, the implications of
hese findings are manifold. They highlight the
otential of imaging techniques such as those de-
cribed in this study to delineate how biological
vents remote from the cardiovascular system may
nfluence disease involving this system. These find-
ngs also underscore the limitations of more gener-
lized biological imaging techniques such as the
easurement of glucose uptake to specifically iden-
ify and localize the key biological events in VAT
hat may influence the development and progres-
ion of CVD. As a consequence, they emphasize
he need for the development of molecular imaging
pproaches that noninvasively target specific cell
ypes and/or biological processes that comprise
AT and contribute to CVD.
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